Argyro Syngelaki

List of Publications by Year
in descending order

200	14,257	19657 61	22166 113
papers	citations	h-index	g-index

207	207	207	9114
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine, 2017, 377, 613-622.	27.0	1,462
2	Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. Fetal Diagnosis and Therapy, 2013, 33, 8-15.	1.4	464
3	Challenges in the diagnosis of fetal nonâ€chromosomal abnormalities at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 90-102.	2.3	385
4	Prediction of early, intermediate and late preâ€eclampsia from maternal factors, biophysical and biochemical markers at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 66-74.	2.3	377
5	Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. American Journal of Obstetrics and Gynecology, 2016, 214, 103.e1-103.e12.	1.3	365
6	Fetal fraction in maternal plasma cellâ€free <scp>DNA</scp> at 11â€“13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound in Obstetrics and Gynecology, 2013, 41, 26-32.	1.7	325
7	Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. American Journal of Obstetrics and Gynecology, 2012, 207, 374.e1-374.e6.	1.3	323
8	Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. New England Journal of Medicine, 2016, 374, 434-443.	27.0	308
9	Competing risks model in screening for preeclampsia by maternal characteristics and medical history. American Journal of Obstetrics and Gynecology, 2015, 213, 62.e1-62.e10.	1.3	280
10	MaternalÂageÂandÂadverseÂpregnancyÂoutcome:ÂaÂcohortÂstudy. Ultrasound in Obstetrics and Gynecology, 2013, 42, 634-643.	1.7	275
11	ASPRE trial: performance of screening for preterm preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2017, 50, 492-495.	1.7	263
12	Multicenter screening for preâ€eclampsia by maternal factors and biomarkers at 11â€“13 weeks' gestation: comparison with <scp>NICE</scp> guidelines and <scp>ACOG</scp> recommendations. Ultrasound in Obstetrics and Gynecology, 2017, 49, 756-760.	1.7	251
13	Chromosome-selective sequencing of maternal plasma cellâ€“free DNA for first-trimester detection of trisomy 21 and trisomy 18. American Journal of Obstetrics and Gynecology, 2012, 206, 322.e1-322.e5.	1.3	245
14	Screening for preâ€eclampsia by maternal factors and biomarkers at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 52, 186-195.	1.7	241
15	Comparison of diagnostic accuracy of early screening for preâ€eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound in Obstetrics and Gynecology, 2018, 51, 743-750.	1.7	219
16	Validation of targeted sequencing of singleâ€nucleotide polymorphisms for nonâ€invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenatal Diagnosis, 2013, 33, 575-579.	2.3	202
17	Protocol for Measurement of Mean Arterial Pressure at 11-13 Weeks' Gestation. Fetal Diagnosis and Therapy, 2012, 31, 42-48.	1.4	197
18	Fetal Medicine Foundation fetal and neonatal population weight charts. Ultrasound in Obstetrics and Gynecology, 2018, 52, 44-51.	1.7	197

#	Article	IF	Citations
19	Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenatal Diagnosis, 2011, 31, 135-141.	2.3	187
20	A Competing Risks Model in Early Screening for Preeclampsia. Fetal Diagnosis and Therapy, 2012, 32, 171-178.	1.4	182
21	Accuracy of competingâ€risks model in screening for preâ€eclampsia by maternal factors and biomarkers at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 751-755.	1.7	182
22	Combined Screening for Preeclampsia and Small for Gestational Age at 11Â–13 Weeks. Fetal Diagnosis and Therapy, 2013, 33, 16-27.	1.4	180
23	Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes. Fetal Diagnosis and Therapy, 2013, 33, 215-223.	1.4	179
24	Diagnosis of fetal nonâ€chromosomal abnormalities on routine ultrasound examination at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 468-476.	1.7	172
25	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. New England Journal of Medicine, 2016, 374, 1044-1052.	27.0	156
26	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology, 2017, 217, 585.e1-585.e5.	1.3	136
27	Predictive performance of the competing risk model in screening for preeclampsia. American Journal of Obstetrics and Gynecology, 2019, 220, 199.e1-199.e13.	1.3	136
28	Fetal Fraction in Maternal Plasma Cell-Free DNA at 11â€“13 Weeksâ€™ Gestation: Effect of Maternal and Fetal Factors. Fetal Diagnosis and Therapy, 2012, 31, 237-243.	1.4	132
29	Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. Ultrasound in Obstetrics and Gynecology, 2019, 53, 465-472.	1.7	122
30	Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2016, 214, 3.e1-3.e9.	1.3	120
31	The role and interaction of imprinted genes in human fetal growth. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140074.	4.0	113
32	Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound in Obstetrics and Gynecology, 2017, 50, 228-235.	1.7	112
33	Birthweight with Gestation and Maternal Characteristics in Live Births and Stillbirths. Fetal Diagnosis and Therapy, 2012, 32, 156-165.	1.4	111
34	Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. Ultrasound in Obstetrics and Gynecology, 2018, 52, 35-43.	1.7	109
35	First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical Testing. Fetal Diagnosis and Therapy, 2014, 35, 118-126.	1.4	108
36	Accuracy of firstâ€trimester combined test in screening for trisomies 21, 18 and 13. Ultrasound in Obstetrics and Gynecology, 2017, 49, 714-720.	1.7	108

#	Article	IF	Citations
37	Firstâ€trimester contingent screening for trisomy 21 by biomarkers and maternal blood cellâ€free <scp>DNA</scp> testing. Ultrasound in Obstetrics and Gynecology, 2013, 42, 41-50.	1.7	107
38	Birth weight in live births and stillbirths. Ultrasound in Obstetrics and Gynecology, 2016, 48, 602-606.	1.7	106
39	A Comprehensive Analysis of Common Genetic Variation Around Six Candidate Loci for Intrahepatic Cholestasis of Pregnancy. American Journal of Gastroenterology, 2014, 109, 76-84.	0.4	103
40	Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11â€“13 weeks. Prenatal Diagnosis, 2011, 31, 75-83.	2.3	101
41	Trisomy 13 detection in the first trimester of pregnancy using a chromosomeâ€selective cellâ€free <scp>DNA</scp> analysis method. Ultrasound in Obstetrics and Gynecology, 2013, 41, 21-25.	1.7	100
42	Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology, 2017, 217, 685.e1-685.e5.	1.3	100
43	An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Scientific Reports, 2017, 7, 11823.	3.3	98
44	Maternal serum placental protein 13 at 11â€“13 weeks of gestation in preeclampsia. Prenatal Diagnosis, 2009, 29, 1103-1108.	2.3	97
45	Contribution of Fetal Tricuspid Regurgitation in First-Trimester Screening for Major Cardiac Defects. Obstetrics and Gynecology, 2011, 117, 1384-1391.	2.4	97
46	Prenatal Detection of Fetal Triploidy from Cell-Free DNA Testing in Maternal Blood. Fetal Diagnosis and Therapy, 2014, 35, 212-217.	1.4	96
47	First-Trimester Screening for Spontaneous Preterm Delivery with Maternal Characteristics and Cervical Length. Fetal Diagnosis and Therapy, 2012, 31, 154-161.	1.4	93
48	Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin Pregnancies. Fetal Diagnosis and Therapy, 2014, 35, 204-211.	1.4	92
49	The 11â€“13â€week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis. Ultrasound in Obstetrics and Gynecology, 2010, 36, 10-14.	1.7	91
50	Prediction and prevention of smallâ€forâ€gestationalâ€age neonates: evidence from SPREE and ASPRE. Ultrasound in Obstetrics and Gynecology, 2018, 52, 52-59.	1.7	91
51	Hidden high rate of preâ€eclampsia in twin compared with singleton pregnancy. Ultrasound in Obstetrics and Gynecology, 2017, 50, 88-92.	1.7	88
52	Umbilical and fetal middle cerebral artery Doppler at 35â€“37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2015, 46, 82-92.	1.7	85
53	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology, 2016, 63, 1287-1298.	7.3	85
54	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. American Journal of Obstetrics and Gynecology, 2018, 218, 612.e1-612.e6.	1.3	84

#	Article	IF	Citations
55	Maternal racial origin and adverse pregnancy outcome: a cohort study. Ultrasound in Obstetrics and Gynecology, 2013, 41, 278-285.	1.7	83
56	Assessment of Fetal Sex Chromosome Aneuploidy Using Directed Cell-Free DNA Analysis. Fetal Diagnosis and Therapy, 2014, 35, 1-6.	1.4	81
57	Contribution of Ductus Venosus Doppler in First-Trimester Screening for Major Cardiac Defects. Fetal Diagnosis and Therapy, 2011, 29, 127-134.	1.4	80
58	Normal Ranges of Embryonic Length, Embryonic Heart Rate, Gestational Sac Diameter and Yolk Sac Diameter at 6â€“10 Weeks. Fetal Diagnosis and Therapy, 2010, 28, 207-219.	1.4	76
59	Maternal hemodynamics at 11â€“13 weeks' gestation and risk of preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2012, 40, 28-34.	1.7	76
60	Ultrasonographic prediction of early miscarriage. Human Reproduction, 2011, 26, 1685-1692.	0.9	69
61	Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35â€“37 weeksâ€™ gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 486.e1-486.e11.	1.3	63
62	Sonographic markers of aneuploidies at 6â€“10weeks of gestation. Early Human Development, 2011, 87, 453-456.	1.8	62
63	Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation, 2021, 144, 670-679.	1.6	61
64	Value of routine ultrasound examination at 35â€“37 weeks' gestation in diagnosis of fetal abnormalities. Ultrasound in Obstetrics and Gynecology, 2020, 55, 75-80.	1.7	59
65	First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. Fetal Diagnosis and Therapy, 2015, 38, 14-21.	1.4	58
66	Screening for preâ€eclampsia at 35â€“37â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 52, 501-506.	1.7	58
67	First-Trimester Prediction of Macrosomia. Fetal Diagnosis and Therapy, 2011, 29, 139-147.	1.4	57
68	Fetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis. Fetal Diagnosis and Therapy, 2014, 35, 199-203.	1.4	55
69	Diagnosis of major heart defects by routine firstâ€trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus. Ultrasound in Obstetrics and Gynecology, 2020, 55, 637-644.	1.7	55
70	Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2012, 31, 87-93.	1.4	54
71	Body Mass Index at 11â€“13 Weeksâ€™ Gestation and Pregnancy Complications. Fetal Diagnosis and Therapy, 2011, 30, 250-265.	1.4	52
72	Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal Abnormalities. Fetal Diagnosis and Therapy, 2014, 35, 174-184.	1.4	51

#	Article	IF	Citations
73	First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing. Fetal Diagnosis and Therapy, 2014, 35, 185-192.	1.4	51
74	Validation of metabolomic models for prediction of early-onset preeclampsia. American Journal of Obstetrics and Gynecology, 2015, 213, 530.e1-530.e10.	1.3	51
75	First trimester maternal serum free Î²â€human chorionic gonadotropin and pregnancyâ€associated plasma protein A in pregnancies complicated by diabetes mellitus. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 410-416.	2.3	50
76	Routine assessment of cerebroplacental ratio at 35â€“37Âweeksâ€™ gestation in the prediction of adverseÂperinatal outcome. American Journal of Obstetrics and Gynecology, 2019, 221, 65.e1-65.e18.	1.3	50
77	Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. American Journal of Obstetrics and Gynecology, 2021, 224, 86.e1-86.e19.	1.3	50
78	A robust secondâ€generation genomeâ€wide test for fetal aneuploidy based on shotgun sequencing cellâ€free DNA in maternal blood. Prenatal Diagnosis, 2013, 33, 707-710.	2.3	49
79	Metabolomic prediction of fetal congenital heart defect in the first trimester. American Journal of Obstetrics and Gynecology, 2014, 211, 240.e1-240.e14.	1.3	48
80	Prevalence and Outcome of Absence of Ductus Venosus at 11⁺⁰ to 13⁺⁶ Weeks. Fetal Diagnosis and Therapy, 2011, 30, 35-40.	1.4	47
81	Screening for preâ€eclampsia at 11â€“13 weeks' gestation: use of pregnancyâ€associated plasma <scp>proteinâ€A</scp>, placental growth factor or both. Ultrasound in Obstetrics and Gynecology, 2020, 56, 400-407.	1.7	47
82	Early Detection of Preeclampsia Using Circulating Small non-coding RNA. Scientific Reports, 2018, 8, 3401.	3.3	46
83	First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus. Metabolism: Clinical and Experimental, 2015, 64, 1485-1489.	3.4	45
84	Outcome of twin pregnancy with two live fetuses at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2020, 55, 32-38.	1.7	45
85	Second-Trimester Uterine Artery Doppler in the Prediction of Stillbirths. Fetal Diagnosis and Therapy, 2013, 33, 28-35.	1.4	43
86	First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. Metabolism: Clinical and Experimental, 2016, 65, 131-137.	3.4	41
87	Prediction of largeâ€forâ€gestationalâ€age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy. Ultrasound in Obstetrics and Gynecology, 2016, 47, 332-339.	1.7	40
88	Prediction of imminent preeclampsia at 35â€“37 weeksÂgestation. American Journal of Obstetrics and Gynecology, 2019, 220, 584.e1-584.e11.	1.3	40
89	Maternal serum placental growth factor at 11â€“13 weeks' gestation and fetal cardiac defects. Ultrasound in Obstetrics and Gynecology, 2013, 42, 169-174.	1.7	39
90	Prediction of stillbirth from maternal demographic and pregnancy characteristics. Ultrasound in Obstetrics and Gynecology, 2016, 48, 607-612.	1.7	39

#	Article	IF	Citations
91	Management of pregnancies after combined screening for preâ€eclampsia at 19â€“24â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 52, 365-372.	1.7	39
92	Routine ultrasound at 32 vs 36 weeks' gestation: prediction of smallâ€forâ€gestationalâ€age neonates. Ultrasound in Obstetrics and Gynecology, 2019, 53, 761-768.	1.7	39
93	Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on firstâ€trimester screening for chromosomal abnormalities. Ultrasound in Obstetrics and Gynecology, 2017, 50, 45-48.	1.7	38
94	Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. American Journal of Obstetrics and Gynecology, 2021, 224, 518.e1-518.e11.	1.3	38
95	Paternally Expressed, Imprinted Insulin-Like Growth Factor-2 in Chorionic Villi Correlates Significantly with Birth Weight. PLoS ONE, 2014, 9, e85454.	2.5	38
96	Two-stage screening for preterm preeclampsia at 11â€“13 weeksâ€™ gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 197.e1-197.e11.	1.3	37
97	Competingâ€risks model in screening for preâ€eclampsia in twin pregnancy according to maternal factors and biomarkers at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 50, 589-595.	1.7	35
98	Metabolomic determination of pathogenesis of late-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 658-664.	1.5	35
99	Integrated Proteomic and Metabolomic prediction of Term Preeclampsia. Scientific Reports, 2017, 7, 16189.	3.3	33
100	Contribution of Method of Conception on Pregnancy Outcome after the 11â€“13 Weeks Scan. Fetal Diagnosis and Therapy, 2011, 30, 9-22.	1.4	32
101	Intertwin discordance in fetal size at 11â€“13â€‰weeks' gestation and pregnancy outcome. Ultrasound in Obstetrics and Gynecology, 2020, 55, 189-197.	1.7	32
102	Competingâ€risks model for prediction of smallâ€forâ€gestationalâ€age neonate from biophysical and biochemical markers at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 57, 52-61.	1.7	32
103	A Mixture Model of Ductus Venosus Pulsatility Index in Screening for Aneuploidies at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2012, 31, 221-229.	1.4	31
104	Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks' Gestation. Fetal Diagnosis and Therapy, 2013, 34, 241-247.	1.4	31
105	Association of chronic hypertension with birth of smallâ€forâ€gestationalâ€age neonate. Ultrasound in Obstetrics and Gynecology, 2017, 50, 361-366.	1.7	31
106	Diet and exercise for preeclampsia prevention in overweight and obese pregnant women: systematic review and meta-analysis. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 3495-3501.	1.5	31
107	Prediction of smallâ€forâ€gestationalâ€age neonates at 35â€“37â€‰weeks' gestation: contribution of maternal factors and growth velocity between 20 and 36â€‰weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 488-495.	1.7	29
108	Cellâ€free <scp>DNA</scp> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10â€“14â€‰weeks and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2021, 58, 178-189.	1.7	28

#	Article	IF	Citations
109	Twoâ€stage approach for prediction of smallâ€forâ€gestationalâ€age neonate and adverse perinatal outcome by routine ultrasound examination at 35â€“37â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 484-491.	1.7	27
110	Reâ€evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: caseâ€“control and cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1635-1644.	2.3	27
111	Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2022, 59, 263-266.	1.7	26
112	Maternal Hemodynamics at 11Â–13 Weeks of Gestation in Pregnancies Delivering Small for Gestational Age Neonates. Fetal Diagnosis and Therapy, 2012, 32, 231-238.	1.4	25
113	Competingâ€risks model in screening for preâ€eclampsia in twin pregnancy by maternal characteristics and medical history. Ultrasound in Obstetrics and Gynecology, 2017, 50, 501-506.	1.7	25
114	Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. Prenatal Diagnosis, 2011, 31, 16-21.	2.3	24
115	Posterior brain in fetuses with trisomy 18, trisomy 13 and triploidy at 11 to 13 weeks' gestation. Prenatal Diagnosis, 2012, 32, 854-858.	2.3	24
116	Fetal major cardiac defects and placental dysfunction at 11â€“13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2018, 51, 194-198.	1.7	24
117	Diagnosis of fetal defects in twin pregnancies at routine 11â€“13â€week ultrasound examination. Ultrasound in Obstetrics and Gynecology, 2020, 55, 474-481.	1.7	24
118	Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening. Ultrasound in Obstetrics and Gynecology, 2017, 49, 460-464.	1.7	23
119	A retrospective multicenter study of the natural history of fetal ovarian cysts. Journal of Pediatric Surgery, 2018, 53, 2019-2022.	1.6	23
120	Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19â€“24 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 624-630.	1.7	21
121	Impaired placentation in women with chronic hypertension who develop preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2017, 50, 496-500.	1.7	21
122	Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 194-200.	1.7	21
123	Prediction of preâ€eclampsia in twin pregnancy by maternal factors and biomarkers at 11â€“13â€‰weeks' gestation: data from <scp>EVENTS</scp> trial. Ultrasound in Obstetrics and Gynecology, 2021, 57, 257-265.	1.7	21
124	A Case-Control Study of Maternal Periconceptual and Pregnancy Recreational Drug Use and Fetal Malformation Using Hair Analysis. PLoS ONE, 2014, 9, e111038.	2.5	20
125	Increased nuchal translucency at 11â€“13 weeks' gestation and outcome in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2020, 55, 318-325.	1.7	20
126	First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein. Fetal Diagnosis and Therapy, 2011, 30, 215-218.	1.4	19

#	Article	IF	Citations
127	Maternal Hemodynamics in Normal Pregnancies at 11â€“13 Weeksâ€™ Gestation. Fetal Diagnosis and Therapy, 2012, 32, 179-185.	1.4	19
128	Prenatal incidence of isolated right aortic arch and double aortic arch. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 2985-2990.	1.5	19
129	Twoâ€stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems. Ultrasound in Obstetrics and Gynecology, 2018, 51, 503-508.	1.7	18
130	Prediction of smallâ€forâ€gestationalâ€age neonates at 35â€“37 weeks' gestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 630-637.	1.7	18
131	Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Downâ€™s syndrome, preterm delivery and preeclampsia. Reproductive Biology and Endocrinology, 2012, 10, 113.	3.3	17
132	Reference Ranges for the Size of the Fetal Cardiac Outflow Tracts From 13 to 36 Weeks Gestation. Circulation: Cardiovascular Imaging, 2018, 11, e007575.	2.6	17
133	Firstâ€trimester screening for trisomies in pregnancies with vanishing twin. Ultrasound in Obstetrics and Gynecology, 2020, 55, 326-331.	1.7	17
134	Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. American Journal of Obstetrics and Gynecology, 2020, 223, 246.e1-246.e10.	1.3	17
135	Galectin-7 Impairs Placentation and Causes Preeclampsia Features in Mice. Hypertension, 2020, 76, 1185-1194.	2.7	17
136	Can Staining of Damaged Proteins in Urine Effectively Predict Preeclampsia?. Fetal Diagnosis and Therapy, 2017, 41, 23-31.	1.4	16
137	Stratification of pregnancy care based on risk of preâ€eclampsia derived from uterine artery Doppler at 19â€“24â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 58, 67-76.	1.7	16
138	Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia. Fetal Diagnosis and Therapy, 2013, 33, 149-155.	1.4	15
139	Competingâ€risksâ€‰modelâ€‰forâ€‰predictionâ€‰ofâ€‰smallâ€forâ€gestationalâ€age neonate from maternal characteristics and serum pregnancyâ€associated plasma <scp>proteinâ€A</scp> at 11â€“13â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2020, 56, 541-548.	1.7	15
140	<scp>STATIN</scp> trial: predictive performance of competingâ€risks model in screening for preâ€eclampsia at 35â€“37â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 69-75.	1.7	15
141	Serum PlGF compared with PAPPâ€A in first trimester screening for preterm preâ€eclampsia: Adjusting for the effect of aspirin treatment. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1308-1317.	2.3	15
142	First-trimester uterine artery Doppler examination in pregnancies complicated by gestational diabetes mellitus with or without pre-eclampsia. Ultrasound in Obstetrics and Gynecology, 2013, 42, 525-529.	1.7	14
143	Competing risks model for prediction of small-for-gestational-age neonates from biophysical markers at 19 to 24 weeksâ€™ gestation. American Journal of Obstetrics and Gynecology, 2021, 225, 530.e1-530.e19.	1.3	14
144	Competingâ€risks model for prediction of smallâ€forâ€gestationalâ€age neonate from estimated fetal weight at 19â€“24â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 57, 917-924.	1.7	14

#	Article	IF	Citations
145	Prediction of outcome in dichorionic twin pregnancies at 6-10 weeks' gestation. American Journal of Obstetrics and Gynecology, 2011, 205, 348.e1-348.e5.	1.3	13
146	Noninvasive Prenatal Testing for Fetal Trisomies in a Routinely Screened First-Trimester Population. Obstetrical and Gynecological Survey, 2013, 68, 173-175.	0.4	13
147	Impaired placental perfusion and major fetal cardiac defects. Ultrasound in Obstetrics and Gynecology, 2019, 53, 68-72.	1.7	13
148	Development and validation of model for prediction of placental dysfunctionâ€•related stillbirth from maternal factors, fetal weight and uterine artery Doppler at midâ€gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 61-68.	1.7	13
149	Chorionic Villus Sampling at 11 to 13 Weeks of Gestation and Hypertensive Disorders in Pregnancy. Obstetrics and Gynecology, 2010, 116, 374-380.	2.4	12
150	First-trimester markers of aneuploidy in women positive for HIV. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 844-848.	2.3	12
151	Association between maternal haemoglobin at 27â€“29weeks gestation and intrauterine growth restriction. Pregnancy Hypertension, 2015, 5, 339-345.	1.4	12
152	Twin pregnancy with two live fetuses at 11â€“13 weeks: effect of one fetal death on pregnancy outcome. Ultrasound in Obstetrics and Gynecology, 2020, 55, 482-488.	1.7	12
153	Secondâ€•and thirdâ€trimester serum levels of growthâ€differentiation factorâ€15 in prediction of preâ€eclampsia. Ultrasound in Obstetrics and Gynecology, 2020, 56, 879-884.	1.7	12
154	Secondâ€trimester contingent screening for smallâ€forâ€gestationalâ€age neonate. Ultrasound in Obstetrics and Gynecology, 2022, 59, 177-184.	1.7	12
155	Predictive performance for placental dysfunction related stillbirth of the competing risks model for smallâ€forâ€gestationalâ€age fetuses. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1530-1537.	2.3	11
156	Maternal serum activin-A at 30â€“33 weeks in the prediction of preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 733-737.	1.5	10
157	Screening for trisomy at 11â€“13 weeks' gestation: use of pregnancyâ€associated plasma <scp>proteinâ€A</scp>, placental growth factor or both. Ultrasound in Obstetrics and Gynecology, 2020, 56, 408-415.	1.7	10
158	Effective Aspirin Treatment of Women at Risk for Preeclampsia Delays the Metabolic Clock of Gestation. Hypertension, 2021, 78, 1398-1410.	2.7	10
159	Fetal intraâ€abdominal bowel dilation in prediction ofÂcomplex gastroschisis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 376-380.	1.7	9
160	Fetal loss after chorionic villus sampling in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2021, 58, 48-55.	1.7	9
161	Reference Ranges for Pulsed-Wave Doppler of the Fetal Cardiac Inflow and Outflow Tracts from 13 to 36ÂWeeksâ€™ Gestation. Journal of the American Society of Echocardiography, 2021, 34, 1007-1016.e10.	2.8	9
162	Risk of fetal loss after chorionic villus sampling in twin pregnancy derived from propensity score matching analysis. Ultrasound in Obstetrics and Gynecology, 2022, 59, 162-168.	1.7	9

#	Article	IF	Citations
163	First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies. Fetal Diagnosis and Therapy, 2011, 30, 194-202.	1.4	8
164	Stratification of pregnancy care based on risk of preâ€eclampsia derived from biophysical and biochemical markers at 19â€“24â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 58, 360-368.	1.7	8
165	Maternal race and preâ€eclampsia: Cohort study and systematic review with metaâ€analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 2082-2093.	2.3	8
166	Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. Obstetric Medicine, 2017, 10, 170-173.	1.1	7
167	Contingent screening in stratification of pregnancy care based on risk of preâ€eclampsia at 19â€“24â€‰weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 58, 553-560.	1.7	7
168	Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis. BMJ Open, 2020, 10, e036981.	1.9	7
169	First-Trimester Screening for Gestational Diabetes Mellitus in Twin Pregnancies. Journal of Clinical Medicine, 2021, 10, 3814.	2.4	6
170	Maternal Race and Stillbirth: Cohort Study and Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3452.	2.4	6
171	Effect of Chorionic Villus Sampling on Uterine Artery Doppler. Fetal Diagnosis and Therapy, 2010, 28, 9-13.	1.4	5
172	Maternal hemoglobin at 27â€“29 weeksâ€™ gestation and severity of pre-eclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 28, 1575-1580.	1.5	5
173	First-trimester metabolomic prediction of stillbirth. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 3435-3441.	1.5	5
174	Fetal fraction of cell free DNA in screening for hypertensive disorders at 11â€“13 weeks. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 5363-5368.	1.5	5
175	Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 227, 294.e1-294.e11.	1.3	5
176	Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies. Prenatal Diagnosis, 2010, 30, 212-215.	2.3	4
177	Screening for late preeclampsia at 35â€“37 weeks by the urinary Congo-red dot paper test. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 5686-5690.	1.5	4
178	Yolk Sac Diameter in Early Pregnancy in Maternal Diabetes Mellitus. Gynecologic and Obstetric Investigation, 2012, 73, 16-20.	1.6	3
179	Assessment of Fetal Sex Chromosome Aneuploidy Using Directed Cell-Free DNA Analysis. Obstetrical and Gynecological Survey, 2014, 69, 249-250.	0.4	3
180	First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment. Clinical Rheumatology, 2019, 38, 1251-1255.	2.2	3

#	Article	IF	Citations
181	Serum leukotriene B4 and hydroxyeicosatetraenoic acid in the prediction of pre-eclampsia. Placenta, 2021, 103, 76-81.	1.5	3
182	Sulfated Progesterone Metabolites That Enhance Insulin Secretion via TRPM3 Are Reduced in Serum From Women With Gestational Diabetes Mellitus. Diabetes, 2022, 71, 837-852.	0.6	3
183	Detection of Embryonic Trisomy 21 in the First Trimester Using Maternal Plasma Cell-Free RNA. Diagnostics, 2022, 12, 1410.	2.6	3
184	OS084. Maternal haemodynamics at 11â€“13 weeks of gestation and adverse pregnancy outcomes. Pregnancy Hypertension, 2012, 2, 223-224.	1.4	2
185	8.4â€…Serum beta defensin concentration in the first trimester is related to genotype, and is higher in women who develop PPROM and deliver before 34 weeks. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2014, 99, A12.1-A12.	2.8	2
186	Metabolomic Prediction of Fetal Congenital Heart Defect in the First Trimester. Obstetrical and Gynecological Survey, 2015, 70, 9-11.	0.4	2
187	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. Obstetrical and Gynecological Survey, 2016, 71, 392-393.	0.4	2
188	Metformin Versus Placebo in Obese Pregnant Women Without Diabetes Mellitus. Obstetrical and Gynecological Survey, 2016, 71, 324-326.	0.4	2
189	Second and third trimester serum levels of HtrA1 in pregnancies affected by pre-eclampsia. Placenta, 2021, 106, 1-6.	1.5	2
190	Competing Risks Model for Prediction of Small for Gestational Age Neonates and the Role of Second Trimester Soluble Fms-like Tyrosine Kinase-1. Journal of Clinical Medicine, 2021, 10, 3786.	2.4	2
191	Maternal Age and Adverse Pregnancy Outcomes. Obstetrical and Gynecological Survey, 2013, 68, 779-781.	0.4	1
192	Association of DEFB1 polymorphisms and in-vivo protein expression: a population-based, case-control study. Lancet, The, 2014, 383, S59.	13.7	1
193	Chronic Hypertension and Adverse Pregnancy Outcome: A Cohort Study. Obstetrical and Gynecological Survey, 2018, 73, 7-8.	0.4	1
194	Chorionic Villus Sampling at 11 to 13 Weeks of Gestation and Hypertensive Disorders in Pregnancy. Obstetrical and Gynecological Survey, 2010, 65, 751-752.	0.4	0
195	OS027. Ethnicity and adverse pregnancy outcomes: A cohort study. Pregnancy Hypertension, 2012, 2, 190-191.	1.4	0
196	4.2â€…Variation in Beta Defensin 1 Genotype is Associated with Preterm Birth. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2013, 98, A4.1-A4.	2.8	0
197	Is variation in copy number of the human beta defensin gene cluster associated with preterm birth?. Lancet, The, 2015, 385, S47.	13.7	0
198	Recreational drug use is associated with a variety of fetal malformations. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, Fa21-Fa21.	2.8	0

#	Article	IF	Citations
199	Estimated fetal weight at midâ€gestation in prediction of preâ€eclampsia in singleton pregnancies. Ultrasound in Obstetrics and Gynecology, 2021, , .	1.7	0
200	Impact of New Definitions of Preeclampsia at Term on Identification of Adverse Maternal and Perinatal Outcomes. Obstetric Anesthesia Digest, 2022, 42, 22-23.	0.1	0